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Recent  clinical  isolates  of key  Gram-negative  and  Gram-positive  bacteria  were  collected  in 2012  from
hospitalised  patients  in medical  centres  in four  European  countries  (France,  Germany,  Italy and  Spain)  and
were  tested  using  standard  broth  microdilution  methodology  to  assess  the  impact  of 4 mg/L  avibactam
on  the  in  vitro  activities  of ceftazidime,  ceftaroline  and  aztreonam.  Against  Enterobacteriaceae,  addition
of  avibactam  signiﬁcantly  enhanced  the  level  of activity  of these  antimicrobials.  MIC90 values  (minimum
inhibitory  concentration  that  inhibits  90%  of the  isolates)  of ceftazidime,  ceftaroline  and  aztreonam  for
Escherichia  coli,  Klebsiella  pneumoniae,  Enterobacter  cloacae,  Enterobacter  aerogenes,  Citrobacter  freundii
and  Morganella  morganii  were  reduced  up  to 128-fold  or  greater  when  combined  with  avibactam.  A
two-fold  reduction  in the  MIC90 of ceftazidime  to  8 mg/L  was  noted  in Pseudomonas  aeruginosa  isolates
when  combined  with  avibactam,  whereas  little  effect  of avibactam  was  noted  on the  MIC  values  of the
test  compounds  when  tested  against  Acinetobacter  baumannii  isolates.  Avibactam  had  little  effect  on the
excellent  activity of ceftazidime,  ceftaroline  and  aztreonam  against  Haemophilus  inﬂuenzae.  It  had  no
impact  on the  in vitro  activity of ceftazidime  and  ceftaroline  against  staphylococci  and  streptococci.  This
study  demonstrates  that  addition  of avibactam  enhances  the  activities  of ceftazidime,  ceftaroline  and
aztreonam  against  Enterobacteriaceae  and  P. aeruginosa  but  not  against  A. baumannii.
1. Introduction
Avibactam, a  novel, potent, non--lactam -lactamase inhibitor
of class A, class C and several class D -lactamases (OXA-48 like
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enzymes), but not  of metallo--lactamases (MBLs), is currently
under clinical development in combination with ceftazidime,
ceftaroline fosamil and aztreonam [1–7]. As part of this develop-
ment, it is important to understand the activity proﬁle of these
antibacterial agents alone and in  combination with avibactam
against routine clinical isolates. In this study, recent Gram-negative
and Gram-positive clinical isolates recovered from hospitalised
patients with respiratory, urinary, intra-abdominal, skin and skin-
structure, and bloodstream infections were prospectively collected
from four European medical centres in France, Germany, Italy and
Spain.
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2. Materials and methods
2.1.  Bacterial isolates
In  total, 606 recent bacterial isolates covering a  wide spectrum
of relevant clinical pathogens were collected from patients in  Hos-
pital Bicêtre (Paris, France), University of Cologne Medical Center
(Cologne, Germany), Siena University Hospital (Siena, Italy) and
Hospital Universitario Ramón y  Cajal (Madrid, Spain). Isolates were
obtained prospectively in a  3-month period in 2012 from spec-
imen sources associated with bloodstream, respiratory, urinary,
intra-abdominal or skin and skin-structure infections. Only a single
isolate per patient was included in the study. Each centre collected
and tested ca. 7 isolates each of different organisms for a  total of
433 Gram-negative and 173 Gram-positive isolates. Detailed num-
bers of included Gram-negative isolates of each species are listed
in Tables 1 and 2.
2.2.  In vitro susceptibility test methods
Minimum inhibitory concentrations (MICs) were determined
following reference Clinical and Laboratory Standards Institute
(CLSI) broth microdilution guidelines [8] using frozen pre-loaded
antibiotic-growth medium microtitre plates prepared by  Thermo
Fisher Scientiﬁc (Oakwood Village, OH) and provided to each centre.
All isolates were tested against the following antibiotics:
ceftazidime, ceftaroline (the active metabolite of ceftaroline
fosamil) and aztreonam (each compound was tested alone and
combined with avibactam at a ﬁxed concentration of 4 mg/L);
cefepime, piperacillin plus tazobactam (4 mg/L); doripenem;
meropenem; colistin; amikacin; levoﬂoxacin; and ampicillin.
The range of concentrations tested was 0.06–128 mg/L for
ceftazidime, ceftazidime-avibactam, aztreonam, aztreonam-
avibactam, piperacillin/tazobactam, cefepime and amikacin,
0.015–32 mg/L for ceftaroline, ceftaroline-avibactam, doripenem,
meropenem, levoﬂoxacin and ampicillin and 0.03–32 mg/L for col-
istin. Avibactam powder was provided to Thermo Fisher Scientiﬁc
by AstraZeneca Pharmaceuticals (Waltham, MA). Escherichia coli
ATCC 25922, E. coli ATCC 35218, Klebsiella pneumoniae ATCC
700603, Pseudomonas aeruginosa ATCC 27853, Staphylococcus
aureus ATCC 29213, Streptococcus pneumoniae ATCC 49619,
Haemophilus inﬂuenzae ATCC 49247 and H. inﬂuenzae ATCC 49766
were used for quality control according to  CLSI guidelines [8].
3.  Results
Susceptibility test results for the Gram-negative isolates are
listed in Tables 1–3. Results with doripenem were very similar
to those of meropenem and were omitted from Tables 1 and 2.
Results for the Gram-positive isolates, except for oxacillin-sensitive
S. aureus (Table 3), are not included in the tables but are described
in the text. Addition of 4 mg/L avibactam restored the activities of
ceftazidime, ceftaroline and aztreonam against the majority of the
Enterobacteriaceae tested (Tables 1–3).
MIC90 values (MIC that inhibits 90% of the isolates) for cef-
tazidime, ceftaroline and aztreonam against E. coli when combined
with avibactam were reduced from 4, >32 and 16 mg/L, respec-
tively, to 0.25 mg/L (Table 1). MIC90 values of >32 mg/L were
obtained for all -lactam antibiotics and levoﬂoxacin against K.
pneumoniae. When combined with avibactam, the MIC90 values for
ceftazidime and aztreonam were reduced from >128 mg/L to 2 mg/L
and 0.5 mg/L, respectively. MIC90 values of ceftaroline (>32 mg/L)
and aztreonam (32 mg/L) in  the Klebsiella oxytoca isolates were
reduced to 0.5 mg/L and 0.25 mg/L, respectively, when combined
with avibactam. There was greater susceptibility to  ceftazidime
Table 1
In  vitro activities of ceftazidime, ceftaroline, aztreonam (with and without avibac-
tam) and comparator antibiotics against Gram-negative bacteria.
Organism (no. of
isolates)/antibiotic
MIC  (mg/L)
Range MIC50 MIC90
Escherichia coli (n = 31)
Ceftazidime ≤0.06–128 0.12 4
Ceftazidime-avibactam ≤0.06–4 0.06 0.25
Ceftaroline 0.06 to  >32 0.25 >32
Ceftaroline-avibactam ≤0.015–1 0.06 0.25
Aztreonam ≤0.06 to >128 0.12 16
Aztreonam-avibactam ≤0.06 to >128 ≤0.06 0.25
Cefepime ≤0.06 to >128 ≤0.06 16
Piperacillin/tazobactam 0.5  to >128 2 64
Meropenem ≤0.015–0.12 ≤0.015 0.12
Colistin 0.25 to >32 0.5  0.5
Amikacin 0.5–4 1 2
Levoﬂoxacin ≤0.015 to >32 ≤0.015 16
Ampicillin 0.25 to >32 >32 >32
Klebsiella pneumoniae (n =  38)
Ceftazidime  ≤0.06 to >128 0.12 >128
Ceftazidime-avibactam ≤0.06 to >128 0.12 2
Ceftaroline 0.06 to  >32 0.25 >32
Ceftaroline-avibactam ≤0.015 to >32 0.12 4
Aztreonam ≤0.06 to >128 ≤0.06 >128
Aztreonam-avibactam ≤0.06–2 ≤0.06 0.5
Cefepime ≤0.06 to >128 ≤0.06 128
Piperacillin/tazobactam 0.5  to >128 4 >128
Meropenem ≤0.015 to >32 0.03 >32
Colistin ≤0.06 to >32 0.5  1
Amikacin 0.5–8 1 4
Levoﬂoxacin ≤0.015–32 0.06 >32
Klebsiella oxytoca (n =  28)
Ceftazidime ≤0.06–128 ≤0.06 2
Ceftazidime-avibactam ≤0.06–128 ≤0.06 1
Ceftaroline 0.03 to  >32 0.25 >32
Ceftaroline-avibactam 0.03–32 0.06 0.5
Aztreonam ≤0.06–128 0.12 32
Aztreonam-avibactam ≤0.06–0.5 ≤0.06 0.25
Cefepime ≤0.06–8 ≤0.06 2
Piperacillin/tazobactam 0.5  to >128 2 >128
Meropenem ≤0.015–1 0.03 0.12
Colistin 0.03–2 0.5  0.5
Amikacin 0.25–8 1 1
Levoﬂoxacin ≤0.015–16 0.03 0.5
Enterobacter cloacae (n =  32)
Ceftazidime ≤0.06 to >128 0.25 >128
Ceftazidime-avibactam ≤0.06–128 0.12 1
Ceftaroline 0.06 to  >32 1 >32
Ceftaroline-avibactam 0.06 to  >32 0.12 1
Aztreonam ≤0.06 to >128 0.25 128
Aztreonam-avibactam ≤0.06–4 ≤0.06 2
Cefepime ≤0.06–128 ≤0.06 32
Piperacillin/tazobactam 0.5  to >128 2 >128
Meropenem ≤0.015–8 0.06 1
Colistin 0.25 to >32 0.25 >32
Amikacin 0.5–8 1 2
Levoﬂoxacin ≤0.015–16 0.06 8
Enterobacter aerogenes (n  =  29)
Ceftazidime  ≤0.06 to >128 0.25 128
Ceftazidime-avibactam ≤0.06–1 0.25 0.5
Ceftaroline ≤0.06–32 1 >32
Ceftaroline-avibactam 0.06–1 0.12 0.5
Aztreonam ≤0.06 to >128 0.25 32
Aztreonam-avibactam ≤0.06–1 0.12 0.5
Cefepime ≤0.06–1 ≤0.06 0.25
Piperacillin/tazobactam 2  to  >128 4 128
Meropenem 0.03–1 0.06 0.12
Colistin 0.12–32 0.25 0.5
Amikacin 0.5–2 1 2
Levoﬂoxacin ≤0.015–16 0.03 8
Citrobacter freundii (n =  25)
Ceftazidime  0.25 to >128 0.25 128
Ceftazidime-avibactam ≤0.06–0.5 0.12 0.5
Ceftaroline 0.12 to >32 0.5  >32
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Table  1 (Continued )
Organism (no. of
isolates)/antibiotic
MIC  (mg/L)
Range MIC50 MIC90
Ceftaroline-avibactam 0.03–0.5 0.12 0.5
Aztreonam ≤0.06–128 0.12 64
Aztreonam-avibactam ≤0.06–0.5 ≤0.06 0.25
Cefepime ≤0.06–32 ≤0.06 1
Piperacillin/tazobactam 1 to >128 2 128
Meropenem ≤0.015–0.12 0.03 0.12
Colistin 0.25–2 0.5 1
Amikacin 0.5–4 1 2
Levoﬂoxacin ≤0.015–16 0.03 2
Citrobacter koseri (n  =  37)
Ceftazidime ≤0.06–16 0.12 0.5
Ceftazidime-avibactam ≤0.06–2 ≤0.06 0.25
Ceftaroline 0.06 to  >32 0.12 1
Ceftaroline-avibactam 0.03–16 0.06 0.25
Aztreonam ≤0.06–128 ≤0.06 0.12
Aztreonam-avibactam ≤0.06–128 ≤0.06 ≤0.06
Cefepime ≤0.06 to  >128 ≤0.06 0.12
Piperacillin/tazobactam 1–32 2 8
Meropenem ≤0.015–0.5 ≤0.015 0.06
Colistin 0.25–2 0.25 0.5
Amikacin 0.25–128 0.5 1
Levoﬂoxacin ≤0.015–16 ≤0.015 0.12
Morganella morganii (n = 24)
Ceftazidime ≤0.06–64 0.5 32
Ceftazidime-avibactam ≤0.06–2 ≤0.06 0.12
Ceftaroline 0.06 to  >32 0.25 >32
Ceftaroline-avibactam ≤0.015–0.5 0.06 0.5
Aztreonam ≤0.06–64 0.12 4
Aztreonam-avibactam ≤0.06–2 ≤0.06 ≤0.06
Cefepime ≤0.06 to  >128 ≤0.06 ≤0.06
Piperacillin/tazobactam 0.12–128 0.25 4
Meropenem ≤0.015–0.5 0.12 0.25
Amikacin 0.5 to >128 1 8
Levoﬂoxacin ≤0.015 to >32 0.03 16
MIC, minimum inhibitory concentration; MIC50/90,  MIC  that inhibits 50% and 90% of
the isolates, respectively.
alone (MIC90, 2 mg/L) among these isolates compared with suscep-
tibility to piperacillin/tazobactam (MIC90, >128/4 mg/L).
Elevated MIC90 values (≥32 mg/L) were noted for ceftazidime,
ceftaroline, aztreonam and piperacillin/tazobactam against Entero-
bacter cloacae and Enterobacter aerogenes isolates (Table 1). MIC90
values for the avibactam combinations were reduced to ≤2  mg/L
for these isolates. MIC90 values for ceftazidime, ceftaroline and
aztreonam for Citrobacter freundii were 128, >32  and 64 mg/L,
respectively, but when combined with avibactam the MIC90 val-
ues were 0.5, 0.5 and 0.25 mg/L, respectively. In contrast to the MIC
values for C. freundii, the MIC90 values for ceftazidime, ceftaroline
and aztreonam for Citrobacter koseri were ≤1  mg/L.
The  MIC90 values for ceftazidime and ceftaroline were ≥16  mg/L
and >32 mg/L, respectively, when tested against the Morganella
morganii and Proteus mirabilis isolates. When combined with
avibactam, the ceftazidime and ceftaroline MIC90 values were
reduced to 0.12 mg/L and 0.5 mg/L, respectively (Tables 1 and 2).
Similar reductions in  MIC90 values were noted with the avibactam
combinations for the Proteus vulgaris isolates (Table 2).
High  MIC90 values were observed for ceftazidime (>128 mg/L),
ceftaroline (>32 mg/L), aztreonam (32 mg/L), cefepime (4 mg/L) and
piperacillin/tazobactam (32 mg/L) for Providencia stuartii (Table 2).
The activities of ceftazidime, ceftaroline and aztreonam were
increased when combined with avibactam as indicated by lower
MIC90 values of 16, 8 and 0.25 mg/L, respectively.
Except for one isolate, Serratia marcescens isolates had low
ceftazidime (≤0.5 mg/L) and aztreonam MICs (≤0.25 mg/L) and
therefore there was little discernible effect with avibactam combi-
nations (Table 2). Ceftazidime and aztreonam MICs for that single
Table 2
In  vitro activities of ceftazidime, ceftaroline, aztreonam (with and without avibac-
tam) and comparator antibiotics against Gram-negative bacteria.
Organism (no. of
isolates)/antibiotic
MIC  (mg/L)
Range MIC50 MIC90
Proteus mirabilis (n = 31)
Ceftazidime ≤0.06–32 ≤0.06 16
Ceftazidime-avibactam ≤0.06–4 ≤0.06 0.12
Ceftaroline 0.06 to >32 0.25 >32
Ceftaroline-avibactam ≤0.06–8 0.12 0.5
Aztreonam ≤0.06–4 ≤0.06 2
Aztreonam-avibactam ≤0.06 ≤0.06 ≤0.06
Cefepime ≤0.06 to >128 ≤0.06 4
Piperacillin/tazobactam 0.25–32 0.25 4
Meropenem ≤0.015–0.5 0.06 0.25
Amikacin 1 to  >128 2 8
Levoﬂoxacin ≤0.015 to >32 0.5 >32
Proteus vulgaris (n  = 15)
Ceftazidime ≤0.06–8 ≤0.06 4
Ceftazidime-avibactam ≤0.06–0.12 ≤0.06 ≤0.06
Ceftaroline 0.12 to >32 8 >32
Ceftaroline-avibactam 0.06–0.25 0.12 0.25
Aztreonam ≤0.06–2 ≤0.06 0.12
Aztreonam-avibactam ≤0.06 ≤0.06 ≤0.06
Cefepime ≤0.06–1 ≤0.06 1
Piperacillin/tazobactam 0.12–0.5 0.25 0.5
Meropenem 0.06–0.12 0.06 0.12
Amikacin 0.25–4 1 2
Levoﬂoxacin ≤0.015–0.25 ≤0.015 0.25
Providencia rettgeri (n  = 8)
Ceftazidime 0.03–0.25 0.12
Ceftazidime-avibactam ≤0.06–0.25 0.06
Ceftaroline  0.03–0.25 0.12
Ceftaroline-avibactam ≤0.015–0.25 0.06
Aztreonam  ≤0.06 ≤0.06
Aztreonam-avibactam ≤0.06 ≤0.06
Cefepime ≤0.06 ≤0.06
Piperacillin/tazobactam 0.25–1 0.25
Meropenem 0.03–0.12 0.06
Amikacin  1–8 2
Levoﬂoxacin ≤0.015–2 0.12
Providencia  stuartii (n  =  13)
Ceftazidime 0.03 to >128 0.5 >128
Ceftazidime-avibactam 0.03–16 0.25 16
Ceftaroline 0.06 to >32 8 >32
Ceftaroline-avibactam 0.06–8 1 8
Aztreonam ≤0.06–64 ≤0.06 32
Aztreonam-avibactam ≤0.06–64 ≤0.06 0.25
Cefepime ≤0.06–16 ≤0.06 4
Piperacillin/tazobactam 0.25–128 2 32
Meropenem 0.06–0.5 0.06 0.25
Amikacin 0.5  to >128 2 8
Levoﬂoxacin 0.12 to >32 2 >32
Serratia marcescens (n =  28)
Ceftazidime ≤0.06–4 0.25 0.5
Ceftazidime-avibactam ≤0.06–0.5 0.12 0.5
Ceftaroline 0.5  to >32 1 8
Ceftaroline-avibactam 0.25–4 0.5 1
Aztreonam ≤0.06–16 0.12 0.5
Aztreonam-avibactam ≤0.06–0.5 ≤0.06 0.25
Cefepime ≤0.06–8 ≤0.06 0.25
Piperacillin/tazobactam 0.5–128 2 4
Meropenem 0.03–0.25 0.06 0.12
Levoﬂoxacin ≤0.015–0.25 0.12 0.25
Pseudomonas aeruginosa (n = 33)
Ceftazidime  0.5–128 4 16
Ceftazidime-avibactam 0.5–16 2 8
Ceftaroline 0.12 to >32 8 >32
Ceftaroline-avibactam 1 to  >32 8 16
Aztreonam 0.25 to >128 8 32
Aztreonam-avibactam ≤0.06–64 8 32
Cefepime 1–64 2 16
Piperacillin/tazobactam 0.5  to >128 8 64
Meropenem ≤0.015 to >32 1 32
Colistin 0.25–4 0.5 1
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Table 2 (Continued )
Organism (no. of
isolates)/antibiotic
MIC  (mg/L)
Range MIC50 MIC90
Amikacin 0.25–128 2 32
Levoﬂoxacin 0.12 to  >32 0.5 32
Acinetobacter baumannii (n  =  30)
Ceftazidime  0.5 to >128 32 >128
Ceftazidime-avibactam 2 to >128 16 64
Ceftaroline 0.5 to >32 16 >32
Ceftaroline-avibactam 0.5 to >32 8 >32
Aztreonam 4 to >128 64 >128
Aztreonam-avibactam 4 to >128 64 >128
Cefepime 0.5 to >128 16 64
Piperacillin/tazobactam ≤0.06 to >128 8 >128
Meropenem 0.12 to  >32 1 >32
Colistin 0.25–2 0.5 1
Amikacin 0.25 to  >128 2 >128
Levoﬂoxacin 0.03 to  >32 1 32
Haemophilus inﬂuenzae (n = 31)
Ceftazidime  ≤0.06–1 ≤0.06 0.25
Ceftazidime-avibactam ≤0.015–2 ≤0.06 ≤0.06
Ceftaroline ≤0.015–2 ≤0.015 0.06
Ceftaroline-avibactam ≤0.015–2 ≤0.015 ≤0.015
Aztreonam  ≤0.06–8 ≤0.06 0.5
Aztreonam-avibactam ≤0.06–8 ≤0.06 0.12
Cefepime ≤0.06–2 ≤0.06 0.12
Piperacillin/tazobactam ≤0.06–0.12 ≤0.06 ≤0.06
Meropenem ≤0.015–0.5 0.06 0.12
Colistin ≤0.06–1 0.5 1
Amikacin 1–4 4 4
Levoﬂoxacin ≤0.015–0.03 ≤0.015 ≤0.015
Ampicillin 0.03 to  >32 0.5 >32
MIC, minimum inhibitory concentration; MIC50/90,  MIC  that inhibits 50% and 90% of
the isolates, respectively.
isolate were reduced from 4 mg/L and 16 mg/L, respectively, to
0.5 mg/L when combined with avibactam.
For P. aeruginosa isolates, there was a  trend towards decreased
MICs of ceftazidime when combined with avibactam as indicated
by a two-fold reduction in the MIC90 (from 16 mg/L to 8 mg/L)
(Table 2). The MIC90 values of the other -lactams, amikacin and
levoﬂoxacin in this study were all ≥16 mg/L.
High  MICs (MIC90,  ≥32  mg/L) were observed for all antibiotics,
except colistin, for the 30 Acinetobacter baumannii isolates (Table 2).
Except for a few isolates with a  two- to three-fold reduction in
the MIC  with the ceftazidime-avibactam combination, addition of
avibactam had little impact on the activity proﬁle of the antibiotics
alone.
All but one of the H. inﬂuenzae isolates, including those
with ampicillin MICs of ≥8  mg/L, had ceftazidime, ceftaroline
and aztreonam MICs ≤0.5  mg/L. There was little reduction in
the MICs of the antibiotics when combined with avibactam
(Table 2).
Ceftaroline was the most potent cephalosporin evaluated
against oxacillin-sensitive S. aureus (n  =  34), with all isolates
inhibited at 1 mg/L (Table 3). In  contrast, the MIC50 (MIC that
inhibits 50% of the isolates)/MIC90 values of ceftazidime and
cefepime were 8/8 and 2/4 mg/L, respectively. Addition of avibac-
tam did not alter the activity of ceftazidime or ceftaroline
Potent activity was also observed with ceftaroline against
oxacillin-resistant S.  aureus (n  =  28) and against Staphylococcus
saprophyticus (n = 15), S. pneumoniae (n  =  30), Streptococcus agalac-
tiae (n = 34) and Streptococcus pyogenes (n  = 24), with MIC90 values
of 2, 1, 0.12, 0.03 and ≤0.015 mg/L, respectively (data not shown).
As noted in the study by Karlowsky et al. [9], addition of avibac-
tam did not have any relevant impact on the MICs of ceftaroline or
ceftazidime against staphylococci or streptococci.
4. Discussion
Avibactam is a -lactamase inhibitor that targets important -
lactamases produced by clinically relevant Gram-negative bacilli,
including class A, C and some class D enzymes [7]. This study was
conducted to  investigate the spectrum and level of activity of cef-
tazidime, ceftaroline and aztreonam in the presence and absence of
avibactam against a  recent collection of geographically distributed
clinical isolates representing commonly encountered relevant bac-
terial species from medical centres in four European countries
(France, Germany, Italy and Spain). Although this study has the
limitation that the potential resistance mechanisms of the isolates
were not  characterised, it clearly provides useful information on
the activity of avibactam in combination with -lactam antibiotics
for which clinical trials are currently being performed.
Against a  wide variety of Enterobacteriaceae, the combina-
tion of avibactam at a  ﬁxed concentration of 4 mg/L substantially
reduced the MIC90 values of ceftazidime, ceftaroline and aztre-
onam in the majority of isolates to levels similar to  those observed
for meropenem and doripenem. These results are similar to
those obtained in  studies carried out in Canada, Latin Amer-
ica, China and the USA [9–12]. Among K.  pneumoniae, several
isolates from one centre had high MICs (≥128 mg/L) for cef-
tazidime, aztreonam, cefepime and piperacillin/tazobactam and
>32 mg/L for ceftaroline, meropenem, doripenem and levoﬂox-
acin. The MICs for ceftazidime-avibactam against all but one
of these isolates were reduced to ≤8  mg/L and for aztreonam-
avibactam all MICs were reduced to ≤2  mg/L. Given the reduced
MIC of aztreonam-avibactam but not that of the corresponding
cephalosporin/avibactam combinations, that isolate likely pro-
duced a MBL  because aztreonam is  not susceptible to  hydrolysis
by these enzymes [13]. Among E. cloacae, the MICs of  cef-
tazidime and ceftaroline against two isolates were not reduced
when combined with avibactam although MICs were reduced
for aztreonam-avibactam, also consistent with the production
of a  MBL  as reasoned above. The MICs against these two
isolates were elevated for cefepime (64 mg/L and 128 mg/L),
piperacillin/tazobactam (>128 mg/L) and meropenem (4 mg/L and
8 mg/L).
Likely  due to the multifactorial nature of resistance in this
species, high MICs were observed for all P. aeruginosa isolates
against all antibiotics in  the study, except for colistin. Among the
collected P. aeruginosa isolates, a  two-fold reduction in the MIC90
was noted for ceftazidime when combined with avibactam, consis-
tent with other studies of P. aeruginosa clinical isolates conducted
in Europe and Canada [14,15]. Except for colistin, high MICs were
shown for all antibiotics for the majority of A. baumannii isolates.
Since avibactam, unlike sulbactam, has no intrinsic activity against
A. baumannii, and resistance to cephalosporins and aztreonam in
these organisms is  usually mediated not  only by class A and class C
-lactamases but also by other resistance mechanisms, the lack of
any effect of the avibactam combinations is not surprising. Avibac-
tam did not have any additional effect over the excellent activity of
ceftazidime, ceftaroline and aztreonam against H. inﬂuenzae. These
data are consistent with the lack of -lactamase-mediated resis-
tance mechanisms to  extended-spectrum cephalosporins in this
species.
As expected, ceftaroline was  more active than ceftazidime and
cefepime against S.  aureus and S. saprophyticus and was  more active
than the other tested antibiotics against oxacillin-resistant iso-
lates of S. aureus (data not shown). Avibactam had no impact on
the activity of ceftaroline or ceftazidime against staphylococci,
which is not surprising since ceftaroline and ceftazidime resis-
tance is not  -lactamase-mediated in these species. As in the case
of staphylococci, ceftaroline was more active than ceftazidime
against S. pneumoniae, S.  pyogenes, Streptococcus milleri group and
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Table  3
Activity of ceftazidime, ceftaroline and aztreonam with and without avibactam (4 mg/L) against selected clinical isolates.
Organism (no. of
isolates)
Antibiotic No.  of isolates inhibited at  an MIC  (mg/L) of
≤0.06 0.125 0.25 0.5  1 2 4 8 16 32  64 ≥128
Escherichia coli (n =  31) Ceftazidime  3 16 5 1 1 2 2 1
Ceftazidime-avibactam  17 10 2 1  1
Ceftaroline 6 6 10 1  2 6
Ceftaroline-avibactam 22 3 4 1  1
Aztreonam  15 8 1 2 2 1 2
Aztreonam-avibactam  22 5 3 1
Klebsiella  spp. (n =  66)a Ceftazidime 24 15 7 2  3 2 1 1 2 9
Ceftazidime-avibactam  32 16 5 4  3 1 2 1 2
Ceftaroline  13 16 11 5  1 4 16
Ceftaroline-avibactam 33 12 8 5  1 4 1 2
Aztreonam  40 7 3 1  2 1 1 1 1 9
Aztreonam-avibactam  45 11 5 3  1 1
Enterobacter spp.
(n  = 61)b
Ceftazidime 5 10 16 3  2 1 1 8 5 10
Ceftazidime-avibactam  11 20 14 9  4 1 2
Ceftaroline 7 8 8 5  7 1 4 21
Ceftaroline-avibactam 22 17 5 9  5 1 2
Aztreonam  26 3 4 1  1 3 1 2 9 5 6
Aztreonam-avibactam  33 8 7 6  3 2 2
Citrobacter freundii
(n  = 25)
Ceftazidime 13 5  1 1 2 3
Ceftazidime-avibactam  7 12 2 4
Ceftaroline 2 9 5  2 1 6
Ceftaroline-avibactam 9 8 4 4
Aztreonam 7 8 2 1  1 2 3 1
Aztreonam-avibactam  16 5 3 1
Pseudomonas
aeruginosa (n = 33)
Ceftazidime  3  2 11 6 6 2 2 1
Ceftazidime-avibactam  1 2  6 13 7 3 1
Ceftaroline  1 1 5 10 4 12
Ceftaroline-avibactam 1  1 5 8 11 6 1
Aztreonam  2 1 9 9 4 6 1 1
Aztreonam-avibactam  1 2 10 10 3 6 1
Staphylococcus  aureus
(oxacillin-sensitive)
(n  = 34)
Ceftazidime 1 9 21 3
Ceftazidime-avibactam 1 7 24 2
Ceftaroline  1 1 18 11  3
Ceftaroline-avibactam 1 1 20 10 2
MIC, minimum inhibitory concentration.
a Klebsiella pneumoniae (n = 38); Klebsiella oxytoca (n  = 28).
b Enterobacter cloacae (n = 32); Enterobacter aerogenes (n = 29).
S. agalactiae isolates. The activity of both antibiotics was  essentially
the same with or without the presence of avibactam.
In conclusion, the results of this study demonstrated that
the combination of 4 mg/L avibactam with ceftazidime, ceftaro-
line or aztreonam broadens their spectrum of activity to include
the majority of -lactam-resistant Enterobacteriaceae against
which these antibiotics alone have poor activity. The activity was
enhanced against many isolates to the extent that their activi-
ties were frequently comparable with, or in  some cases greater
than, those of the carbapenems. An isolate-dependent enhance-
ment of activity was observed with the avibactam combinations
against P. aeruginosa isolates, resulting in a  ceftazidime-avibactam
MIC90 of 8 mg/L. Avibactam combinations were not  active against
A. baumannii. Furthermore, avibactam had no impact on the
in vitro activity of ceftaroline or ceftazidime against staphylo-
cocci and streptococci. This is  consistent with the absence
of -lactamase-mediated resistance mechanisms to extended-
spectrum cephalosporins among these genera.
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